Study guide
28.2 Critical Data, Acquisition Tools and Interim Findings
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
28.2 Critical Data, Acquisition Tools and Interim Findings
Key Takeaways Explain This Topic AI
Critical variables and processes depend on the trial’s protections and scientific question.
Data transfers need integrity, confidentiality and appropriate reconciliation.
Interim findings require controlled access and documented operational action.
Last updated: October 2026
Critical Data, Acquisition Tools and Interim Findings
Data acquisition tools include CRFs/eCRFs, source worksheets, participant diaries, electronic patient-reported outcomes and other instruments used to capture trial information. E6(R3) expects fit-for-purpose tools, suitable procedures and proportionate controls. A tool should support the protocol's intended data and avoid unnecessary transcription or burden. A form containing every imaginable field can create more error without improving the trial's conclusions.
Compare the tool with the protocol: variables, definitions, units, assessment timing, response options and relevant instructions. Establish where the original record is created, how it reaches the sponsor and what metadata support interpretation. Some eCRF fields are transcribed from other records; others may be the first direct capture. Do not assume a CRF can never be source or that direct capture needs a duplicate paper original.
Critical variables and processes
A critical variable is important to participant protection or reliable interpretation, such as a primary endpoint, eligibility measurement or relevant safety result. A critical process might be consent, randomisation, dose authorisation or delivery of an urgent result. The exact set depends on the trial. A vital sign cannot be universally labelled noncritical simply because it is routine in another study.
- Criticality question Example Potential control
- Could an error harm a participant? Wrong dose unit Clear tool, validation and qualified review
Could it change the scientific conclusion? Incorrect primary-endpoint timing Precise instructions and targeted verification
- Could it undermine a protection? Consent version not controlled Approved-material release and process review
- Could it cause systematic bias? Unblinded assessor Role/access separation and training
Quality by design considers these factors before collection. Monitoring then tests whether the controls work and updates risk assessment when experience shows a gap. A large number of completed fields does not establish that a critical outcome was measured correctly.
Participant-generated data
Electronic questionnaires can use timestamps and controlled completion windows to reduce retrospective completion. They do not eliminate every risk: a caregiver might answer for a participant, a device clock may be wrong, a transmission may fail or the software may show the wrong language/instrument version. Provide suitable training/support and define how omissions and technical problems are handled.
Do not fill missed diary days from memory merely to make a completion rate appear satisfactory. Preserve actual entry timing and distinguish observation time from transmission time. A late upload can contain correctly time-stamped contemporaneous entries stored offline; conversely, a timely upload does not prove the intended person answered. Review relevant metadata and the designed workflow.
Bring-your-own-device and provided-device approaches have different access, compatibility, privacy and support considerations. Neither is inherently always more compliant. Assess intended users, instrument validity, accessibility and continuity. The protocol and system instructions should make participant responsibilities and urgent contact routes clear.
Data transfers and transmission
When data move between systems, use appropriate validated processes or reconciliation to preserve integrity and confidentiality. Verify participant/visit identifiers, units, mappings, missing records, duplicates and relevant metadata. A transfer can succeed technically while mapping a laboratory unit incorrectly or omitting an important status. Define who investigates and resolves such issues.
A monitor may notice that site source and central listings consistently differ by a factor of ten. Do not change every site record to match the listing. Establish the original values and units, assess whether the problem is transcription, transformation or mapping, and involve the responsible data/technical function. Evaluate affected safety decisions and analyses as well as the visible discrepancy.
Interim safety and efficacy findings
An interim analysis can influence continuation, modification or stopping. Its purpose, timing, access and methods should be prespecified as appropriate, with safeguards against bias. A DMC may review unblinded safety and relevant efficacy data under its charter. Other appropriately designated functions may also have limited unblinded access; a universal claim that only one committee ever sees treatment identity is inaccurate.
Maintain separation for people whose conduct or assessment could be influenced. Interim knowledge should not cause sites to change recruitment, assess outcomes differently or selectively collect data outside authorised changes. The sponsor evaluates recommendations and communicates operational instructions through controlled channels. Participant safety takes priority, but a concerning trend need not be publicised to every blinded staff member with treatment labels attached.
Monitoring a resulting action
If the sponsor pauses a cohort after a safety recommendation, verify scope, receipt, site implementation, participant care and relevant product handling. Preserve the decision and communication record and clarify conditions for resumption. If an analysis requires a data cut, verify the intended period and dataset version rather than assuming the entire global study must be complete.
The CRA helps ensure meaningful data are available and decisions become appropriate site action. They do not interpret an interim p-value independently to declare efficacy, unblind the site or waive continuing assessments. Reliable data quality combines sound design, suitable tools, traceable processing and controlled use of emerging information.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9(R1) .